Cytodyn has shown us via investor conference call�

Cytodyn has shown us via investor conference call’s in the past a slide deck covering key target areas like HIV, TNBC Cancer etc. with “market potential” related monetary figures to mesmerize their audience, presumably expanded to potential suitors…my take when I saw them was: lengthy, detailed. Held my interest but to a great extent because I have done my DD and am already interested. Any marketing presentation or “pitch” needs to be succinct while probing the needed depth where appropriate. With respect to Leronlimab it should also drive home the point that it is an immune modulator that sits at the heart of immune regulation and the inflammatory response and make the case for multiple potential indications…in short make the case for being a platform molecule. I can envision this argument on a debut slide to catch everyone’s attention out of the gate so they are not drifting to their smartphone. At the center of concentric circles, a decent sized “fusion reaction” graphic fueled by money…this is where BP sits. Segmented concentrics pull out key markets…the cancer “pie” further subdivides to the key known science backed CCR5 targets such as breast, CRC, prostate etc. On the outer-rim are target market potential dollar amounts, summarized in large bold print at the top…an asterisk points to a last slide(s) with links to all the innumerable published articles that substantiate the case and prove you are not blowing smoke.

We don’t need this slide but any potential suitor should understand it before any more talking points where the fog can set in.

Make the case Cytodyn. Pick the largest market cap mega-BP entities who have development interest overlapping this platform molecule coverage, that want to see their treasury go super-nova. Make them want to run, not walk for their checkbook. Collectively you have connections to these companies…leverage them. We want to see the super-nova, hopefully in our lifetime.